Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9477)	3/31/1999 4:07:00 PM
From: aknahow	Respond to of 17367

Someone, Sra. Pajarita, has an interest in water. Was/is this interest personal or does it reflect something? Bottom of the ice berg perhaps. BTW Bluegreen if you sat on Bob's, tip of the ice berg, for 4 hours what would we have to call you? Hint, if you take your dog with you, will you call him Old Blue?

To: Bluegreen who wrote (9477)	3/31/1999 8:54:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

1. A method of treating chlamydial infections comprising administering to a subject suffering from a chlamydial infection a therapeutically effective amount of a bactericidal/permeability-increasing (BPI) protein product. 2. The method of claim 1 wherein the BPI protein product is BPI holoprotein, rBPI.sub.23 or rBPI.sub.21. 3. The method of claim 1 wherein the BPI protein product is administered at a dose of between 1 .mu.g/kg to 100 mg/kg per day. 4. The method of claim 1 wherein the BPI protein product is administered topically at a unit dose of between 1 .mu.g/mL to 1 gm/mL. 5. The method of claim 1 comprising the additional step of administering a non-BPI anti-chlamydial agent. 6. The method of claim 1 wherein the subject is suffering from coronary artery disease. 7. The method of claim 1 wherein the BPI protein product is an N-terminal fragment of BPI or dimeric form thereof. 8. The method of claim 7 wherein the N-terminal fragment has a molecular weight of about 21 kD to 25 kD. 9. The method of claim 1 wherein the subject is infected by a chlamydial species selected from the group consisting of C. trachomatic, C. pneumoniae, C. psittaci and C. pecorum species. 10. The method of claim 9 wherein the chlamydial species is C. trachomatis. 11. A method of killing or inhibiting replication of chlamydia comprising contacting the chlamydia with a bactericidal/permeability-increasing (BPI) protein product. 12. The method of claim 11 further comprising contacting the chlamydia with a non-BPI anti-chlamydial agent. 13. A method of killing or inhibiting replication of chlamydia in a subject suffering from coronary artery disease comprising contacting the chlamydia with a bactericidal/permeability-increasing protein product. Just one more reason why I hope XOMA makes it with the Meningococcemia trial. Xoma needs the resources to develop other interesting products. Why they have not given any p.r. to this patent is beyond me. Chlamydia is a big problem world wide. Existing treatments are less than effective. 25 to 30% failure rate, I think.